Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • Resource and Technical Advances
    • Clinical Medicine
    • Reviews
    • Editorials
    • Perspectives
    • Top read articles
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
Muscle-specific ER-associated degradation maintains postnatal muscle hypertrophy and systemic energy metabolism
Benedict Abdon, … , Sander Kersten, Ling Qi
Benedict Abdon, … , Sander Kersten, Ling Qi
Published August 3, 2023
Citation Information: JCI Insight. 2023;8(17):e170387. https://doi.org/10.1172/jci.insight.170387.
View: Text | PDF
Research Article Cell biology Muscle biology

Muscle-specific ER-associated degradation maintains postnatal muscle hypertrophy and systemic energy metabolism

  • Text
  • PDF
Abstract

The growth of skeletal muscle relies on a delicate equilibrium between protein synthesis and degradation; however, how proteostasis is managed in the endoplasmic reticulum (ER) is largely unknown. Here, we report that the SEL1L-HRD1 ER-associated degradation (ERAD) complex, the primary molecular machinery that degrades misfolded proteins in the ER, is vital to maintain postnatal muscle growth and systemic energy balance. Myocyte-specific SEL1L deletion blunts the hypertrophic phase of muscle growth, resulting in a net zero gain of muscle mass during this developmental period and a 30% reduction in overall body growth. In addition, myocyte-specific SEL1L deletion triggered a systemic reprogramming of metabolism characterized by improved glucose sensitivity, enhanced beigeing of adipocytes, and resistance to diet-induced obesity. These effects were partially mediated by the upregulation of the myokine FGF21. These findings highlight the pivotal role of SEL1L-HRD1 ERAD activity in skeletal myocytes for postnatal muscle growth, and its physiological integration in maintaining whole-body energy balance.

Authors

Benedict Abdon, Yusheng Liang, Débora da Luz Scheffer, Mauricio Torres, Neha Shrestha, Rachel B. Reinert, You Lu, Brent Pederson, Amara Bugarin-Lapuz, Sander Kersten, Ling Qi

×

Figure 1

SEL1L-HRD1 ERAD expression in muscles.

Options: View larger image (or click on image) Download as PowerPoint
SEL1L-HRD1 ERAD expression in muscles.
(A) Representative Western blot o...
(A) Representative Western blot of SEL1L, HRD1, and BiP in indicated mouse tissues (n = 3 mice). (B) Representative confocal image of tibialis anterior cross sections stained for SEL1L and DAPI (n = 3 mice). Dotted line indicates individual myofiber (MF). N, nucleus. White arrows indicate perinuclear SEL1L expression. Yellow arrows indicate interfibrillar SEL1L expression. (C–E) Representative confocal images of isolated EDL myofibers stained for SEL1L, ER marker KDEL, or the SR marker ryanodine receptor 1 (RYR1) (n = 3 mice). White arrows indicate regions of KDEL and SEL1L colocalization. Dashed line represents intermyofibrillar ER localization (C and D). Yellow arrows in E indicate RYR1/SR localization, with dashed lines indicating intermyofibrillar SR location. Boxes indicate high-magnification inset. (F and G) Western blot analysis and quantitation of SEL1L-HRD1 and ER chaperones in quadriceps muscle of 4-, 8-, 12-, and 20-week-old WT C57BL/6J mice (n = 6–8 mice per time point). Data presented as mean ± SEM, normalized to the 4-week time point. NS, P > 0.05; *P < 0.05; **P < 0.01; ***P < 0.001 determined by 1-way ANOVA with Dunnett’s multiple-comparison test.

Copyright © 2023 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts